As Caliper Eyes Further Revenue Growth, It Extends Technology to Adherent Cells | GenomeWeb

As Hopkinton, Mass.-based Caliper Life Sciences prepares to release its first-quarter financial results, the company anticipates its seventh consecutive quarter of year-over-year revenue growth.

Caliper attributes this growth to the fact that its LabChip microfluidics platform and liquid handling and laboratory robotics continue to gain traction among pharma. The growth is also due in part to Caliper's ongoing addition of cell-based assay capabilities to its flagship LabChip platform, and to pharma's growing interest in cellular assay technologies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.